KPTI (47) MCRB (54) ACTU (43) QNTM (58) ⌘ Pro Terminal →

Quoin Pharmaceuticals Ltd. (QNRX) — RQD Stock Rating Cockpit

$4.15 +0.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Quoin Pharmaceuticals Ltd. (QNRX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $19.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QNRX)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

49.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $3$4.15H: $24

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on QNRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (52)

16/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like QNRX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QNRX)

✓Walkthrough of QNRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QNRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.96%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.19H $4.54L $3.87C $4.15VOL 36.6K

RES: $9.13SUP: $3.86SMA50: $5.43SMA200: $6.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QNRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QNRX Butterfly Map → + Track QNRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QNRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QNRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QNRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QNRX)

Health Care Rank #392 of 1016 ⚔️ KPTI vs QNRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QNRX vs. KPTI, MCRB, ACTU, QNTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Quoin Pharmaceuticals Ltd. (QNRX) ranks #392 by composite RQD confidence (48/100, grade D) and #835 by equity capitalization ($19.9M). Within this direct 5-issuer industry benchmark cohort, QNRX leads on earnings valuation at N/A trailing P/E, while QNRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with QNRX at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QNRX ACTIVE Quoin Pharmaceuticals Ltd.	D	48/100	—	—	-35.0%	+0.97%	$19.9M	Benchmark Subject
KPTI Karyopharm Therapeutics Inc.	D	47/100	—	—	-35.0%	+5.73%	$20.0M	/kpti-vs-qnrx →
MCRB Seres Therapeutics Inc.	D+	54/100	—	—	-35.0%	+8.94%	$19.6M	/mcrb-vs-qnrx →
ACTU Actuate Therapeutics Inc.	D-	43/100	—	—	-35.0%	-3.21%	$20.4M	/actu-vs-qnrx →
QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares	D+	58/100	—	—	—	+2.95%	$20.7M	/qntm-vs-qnrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671502

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quoin Pharmaceuticals Ltd. (QNRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$15.8M, operating cash flow of -$13.5M, and free cash flow of -$13.5M (-72.3% YoY). On the balance sheet, QNRX closed FY2025 with $20.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$15.8M	-$13.5M	-$13.5M	$20.4M	—
FY2024 (FY)	2024-12-31	$0	-$9.0M	-$7.9M	-$7.9M	$15.7M	—
FY2023 (FY)	2023-12-31	$0	-$8.7M	-$7.9M	-$7.9M	—	—

3. QNRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QNRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $4.15 (+0.97% 1D, market cap $19.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, QNRX ranks #392 in composite RQD confidence.

How does QNRX compare to KPTI and MCRB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNRX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KPTI (Karyopharm Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $20.0M) and MCRB (Seres Therapeutics Inc.) posts a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $19.6M). Among the 5-stock peer group, QNRX leads on earnings multiple (N/A) while QNRX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QNRX?

Per QNRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671502), Quoin Pharmaceuticals Ltd. generated $0 in revenue, -$15.8M in net income, and -$13.5M in free cash flow against $20.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QNRX trading relative to its 50-day, 200-day, and 52-week technical levels?

QNRX last traded at $4.15 (+0.97% on volume of 3,344 shares), positioning the stock -23.57% below its 50-day simple moving average ($5.43) and -31.40% below its 200-day simple moving average ($6.05). Across its 52-week range of $3.25 to $23.50, QNRX sits at the 4.4% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.63 to $4.67).

QNRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell QNRX stock right now?

Quoin Pharmaceuticals Ltd. (QNRX) currently earns a Roarable Rating of D (Sell — SELL) with 48/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is QNRX's 12-month price target and RQD AI Jury consensus?

QNRX's 12-month base price target is $3.96 (range $3.09 to $24.68), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: QNRX RQD Cockpit QNRX 12M Forecast QNRX Earnings & Move QNRX Dividends & DRIP QNRX Insiders & 13F QNRX Whale Options QNRX Profit Sankey QNRX News & Why